title: Double-phase parathyroid 99mTc-Sestamibi scintigraphy in chronic haemodialysis patients: correlation with biochemical markers of parathyroid function.
abstract: 99mTc-Sestamibi identifies the presence of hyperfunctioning autonomous parathyroid glands in patients with secondary hyperparathyroidism (SHP). The objectives of this study were: (i) to evaluate the interdependence between biochemical markers of SHP and 99mTc-Sestamibi uptake; and (ii) to determine whether 99mTc-Sestamibi uptake could be efficiently predicted by any combination of the former variables. Double-phase parathyroid 99mTc-Sestamibi uptake and total serum calcium, phosphorus, intact parathormone, 25-OH vitamin D and 1,25(OH) vitamin D determinations were performed simultaneously in 74 patients (36 female, 38 male) with SHP. Planar images of the neck and upper thorax were obtained in anterior view, 15 min (early phase) and 120 min (delayed phase) after the injection of 740 MBq of 99mTc-Sestamibi. In each patient, a final parathyroid/thyroid (P/T) activity index was obtained by adding the results of the P/T index of all parathyroid lesions. There was a significant correlation between intact parathormone levels and delayed 99mTc-Sestamibi uptake ( r=0.656; P<0.01). Of all the variables, intact parathormone was the only significant predictor of delayed 99Tc-Sestamibi uptake ( r=0.487; P<0.001). Calcium, phosphorus, vitamin D metabolites, age, gender, time spent on haemodialysis and cause of chronic renal failure displayed no significant correlation with 99mTc-Sestamibi uptake. It can be concluded that 99mTc-Sestamibi uptake is a potential predictor of parathyroid function in SHP patients. Hence, 99mTc-Sestamibi scintigraphy could be useful to assess parathyroid function and in the clinical follow-up of these patients.
authors.affiliation: Nuclear Medicine Department, Renal Transplant Unit and Hormonal Laboratory, Hospital Clínic de Barcelona, Barcelona, Spain. dfuster@clinic.ub.es
authors.forename: D
authors.initials: D
authors.lastname: Fuster
authors.forename: J
authors.initials: J
authors.lastname: Ybarra
authors.forename: J V
authors.initials: JV
authors.lastname: Torregrosa
authors.forename: X
authors.initials: X
authors.lastname: Setoain
authors.forename: F
authors.initials: F
authors.lastname: Martin
authors.forename: M L
authors.initials: ML
authors.lastname: Ortega
authors.forename: M J
authors.initials: MJ
authors.lastname: Martinez-Osaba
authors.forename: S
authors.initials: S
authors.lastname: Fuertes
authors.forename: F
authors.initials: F
authors.lastname: Pons
mesh_terms: D000367:Age Factors; D015415:Biomarkers / Q000097:blood; D002118:Calcium / Q000097:blood; D004100:Dihydroxycholecalciferols / Q000097:blood; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood* / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D010280:Parathyroid Glands / Q000000981:diagnostic imaging / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood*; D010758:Phosphorus / Q000097:blood; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D006435:Renal Dialysis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012737:Sex Factors; D013223:Statistics as Topic; D017256:Technetium Tc 99m Sestamibi; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D015415:Biomarkers; D004100:Dihydroxycholecalciferols; D010281:Parathyroid Hormone; D019275:Radiopharmaceuticals; D014807:Vitamin D; D010758:Phosphorus; D017256:Technetium Tc 99m Sestamibi; C104450:25-hydroxyvitamin D; D002118:Calcium